DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Xcopri is a drug marketed by Sk Life and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-two patent family members in eighteen countries.
The generic ingredient in XCOPRI is cenobamate. Additional details are available on the cenobamate profile page.
Xcopri will be eligible for patent challenges on March 10, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 30, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for XCOPRI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Sk Life||XCOPRI||cenobamate||TABLET;ORAL||212839-001||Mar 10, 2020||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Sk Life||XCOPRI||cenobamate||TABLET;ORAL||212839-004||Mar 10, 2020||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Sk Life||XCOPRI||cenobamate||TABLET;ORAL||212839-002||Mar 10, 2020||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|Sk Life||XCOPRI||cenobamate||TABLET;ORAL||212839-006||Mar 10, 2020||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|